A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression.
Phase 2
- Conditions
- PD patients
- Registration Number
- JPRN-UMIN000016893
- Lead Sponsor
- Ehime University Hospital Dept. of Clinical pharmacology and Neurology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
-Concomitant use of duloxetine within 2 weeks -Subject with contraindication to duloxetine -Suicidal ideation -Renal transplantation or dialysis therapy -History of any kidney diseases or baseline creatinine clearance below 30 (mL/min/1.73 m2) -Woman who are pregnant or lactating -Evidence of clinically significant disease - Subjects on antipsychotics -Have had multiple drug allergies or a severe drug reaction -History of drug or alcohol dependency or abuse -History of treatment with antipsychotics within 1 year before Visit 1 - Other inadequate status for clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual analogue scale
- Secondary Outcome Measures
Name Time Method The short-form McGill Pain Questionnaire, Beck's Depression Scale, Parkinson's Disease Questionnaire-39, Unified Parkinson's Disease Rating Scale, Up and Go Test